Lehrer Steven, Rheinstein Peter H
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.;
Department of Pharmacology, Severn Health Solutions, Severna Park, MD, U.S.A.
In Vivo. 2025 Jul-Aug;39(4):2066-2072. doi: 10.21873/invivo.14001.
BACKGROUND/AIM: The aim of the present study was to investigate on the repurposing of glatiramer acetate (GA), a drug traditionally used to treat multiple sclerosis, as well as explore GA potential to treat cardiac ischemia in rodent models. It has been shown that GA exerts immunomodulatory effects that reduced inflammation and increased repair of heart tissue following myocardial infarction (MI) in mice and rats. GA has been shown to enhance cardiac function by promoting angiogenesis, reducing scar tissue, and protecting cardiomyocytes from ischemic damage.
Risteys/FinnGen and MedWatch/OpenVigil data were used to assess the effects of GA on the heart.
There was significantly less ischemic heart disease (p<0.001, Fisher's exact test) and cardiovascular disease (p<0.001) in 457 subjects with MS who used GA in Risteys/FinnGen. Analysis of MedWatch/OpenVigil data showed a significantly reduced risk of acute MI in individuals using GA, with a proportional reporting ratio (PRR) of 0.101, indicating statistical significance at the 95% confidence level. Additionally, analysis of MedWatch/OpenVigil data indicated a decreased risk of cardiovascular disease in GA users, with a PRR of 0.345, reaching statistical significance at the 95% confidence level.
Despite rare adverse cardiovascular side-effects and given its established safety profile, GA shows promise as a novel treatment option for heart disease. Further studies could lead to an important new use of GA especially in patients who do not receive tissue plasminogen activator within the first few hours following an MI.
背景/目的：本研究旨在探讨传统用于治疗多发性硬化症的醋酸格拉替雷（GA）的新用途，并探索其在啮齿动物模型中治疗心脏缺血的潜力。研究表明，GA具有免疫调节作用，可减轻炎症并促进小鼠和大鼠心肌梗死后心脏组织的修复。GA已被证明可通过促进血管生成、减少瘢痕组织以及保护心肌细胞免受缺血损伤来增强心脏功能。
使用Risteys/FinnGen和MedWatch/OpenVigil数据评估GA对心脏的影响。
在Risteys/FinnGen中，457名使用GA的多发性硬化症患者的缺血性心脏病（p<0.001，Fisher精确检验）和心血管疾病（p<0.001）明显较少。对MedWatch/OpenVigil数据的分析显示，使用GA的个体急性心肌梗死风险显著降低，比例报告率（PRR）为0.101，表明在95%置信水平具有统计学意义。此外，对MedWatch/OpenVigil数据的分析表明，GA使用者心血管疾病风险降低，PRR为0.345，在95%置信水平达到统计学意义。
尽管存在罕见的心血管不良副作用，且鉴于其已确立的安全性，GA有望成为心脏病的一种新治疗选择。进一步的研究可能会带来GA的重要新用途，特别是在心肌梗死后最初几小时内未接受组织纤溶酶原激活剂治疗的患者中。
